Moneycontrol PRO
Live: Live: Money Management Mantra For Defence Personnel
you are here: HomeNewsBusiness

Alkem Laboratories says USFDA inspection at Taloja facility ends with 'zero' observations

The US Food and Drug Administration (USFDA) had conducted a remote and virtual bio-analytical inspection of the company's Bioequivalence Center located at Taloja, Maharashtra from July 26-28, 2021, Alkem Laboratories said in a regulatory filing.

July 29, 2021 / 01:24 PM IST
Alkem Laboratories | LIC increased stake in the company to 3.42 percent in December quarter from 2.27 percent in September quarter, but HDFC Life Insurance Company's name did not appear in December quarter, which had held 1.07 percent stake in the company in September quarter.

Alkem Laboratories | LIC increased stake in the company to 3.42 percent in December quarter from 2.27 percent in September quarter, but HDFC Life Insurance Company's name did not appear in December quarter, which had held 1.07 percent stake in the company in September quarter.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Alkem Laboratories on Thursday said the US health regulator has conducted an inspection of its Taloja facility in Maharashtra, and it ended with "zero" observations.

The US Food and Drug Administration (USFDA) had conducted a remote and virtual bio-analytical inspection of the company's Bioequivalence Center located at Taloja, Maharashtra from July 26-28, 2021, Alkem Laboratories said in a regulatory filing.

At the end of the inspection, no form 483 was issued, the company added.

A form 483 is issued by the USFDA to notify a company's management of any objectionable condition at its manufacturing facility. The form is issued after completing the inspection.

Shares of Alkem Laboratories were trading 0.30 percent lower at Rs 3,362.05 apiece on BSE.
PTI
first published: Jul 29, 2021 01:25 pm
Sections
ISO 27001 - BSI Assurance Mark